Payment overview · 2025
General Payments
$13.98
1 reported records · 1 companies
Healthcare provider profile · identity verified
Tejinder Singh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · UPLAND, CA · NPI 1104820729
Verified facts
What the public records show
CMS Open Payments records show Tejinder Singh, MD received $13.98 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.98 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.98 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 748 | 206 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 477 | 134 |
| Omeprazole | Omeprazole | 448 | 126 |
| Metformin Hcl | Metformin Hcl | 419 | 113 |
| Losartan Potassium | Losartan Potassium | 316 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 85 |
| Lorazepam | Lorazepam | 236 | 60 |
| Gabapentin | Gabapentin | 225 | 63 |
| Meloxicam | Meloxicam | 223 | 77 |
| Pravastatin Sodium | Pravastatin Sodium | 223 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 87 |
| Furosemide | Furosemide | 205 | 55 |
| Trazodone Hcl | Trazodone Hcl | 204 | 50 |
| Carvedilol | Carvedilol | 200 | 44 |
| Lisinopril | Lisinopril | 193 | 52 |
| Simvastatin | Simvastatin | 193 | 46 |
| Potassium Chloride | Potassium Chloride | 179 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 171 | 47 |
| Jardiance | Empagliflozin | 167 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 159 | 44 |
| Eliquis | Apixaban | 155 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 40 |
| Famotidine | Famotidine | 133 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 40 |
| Januvia | Sitagliptin Phosphate | 116 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 113 | 29 |
| Sertraline Hcl | Sertraline Hcl | 110 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 105 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 28 |
| Tramadol Hcl | Tramadol Hcl | 102 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 48 |
| Alendronate Sodium | Alendronate Sodium | 98 | 21 |
| Allopurinol | Allopurinol | 88 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 20 |
| Donepezil Hcl | Donepezil Hcl | 80 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 60 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 22 |
| Myrbetriq | Mirabegron | 78 | 23 |
| Lovastatin | Lovastatin | 72 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 66 | 22 |
| Ezetimibe | Ezetimibe | 65 | 22 |
| Finasteride | Finasteride | 64 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 37 |
| Risperidone | Risperidone | 63 | 21 |
| Ammonium Lactate | Ammonium Lactate | 62 | 34 |
| Clonazepam | Clonazepam | 62 | 25 |
| Fenofibrate | Fenofibrate | 62 | 20 |
| Ozempic | Semaglutide | 62 | 14 |
| Buspirone Hcl | Buspirone Hcl | 60 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 19 |
| Mirtazapine | Mirtazapine | 58 | 11 |
| Clonidine Hcl | Clonidine Hcl | 55 | 25 |
| Midodrine Hcl | Midodrine Hcl | 55 | 14 |
| Olanzapine | Olanzapine | 55 | 11 |
| Telmisartan | Telmisartan | 55 | 17 |
| Atenolol | Atenolol | 54 | 18 |
| Alprazolam | Alprazolam | 53 | 14 |
| Doxepin Hcl | Doxepin Hcl | 53 | 17 |
| Enalapril Maleate | Enalapril Maleate | 53 | 13 |
| Glipizide | Glipizide | 50 | 14 |
| Risedronate Sodium | Risedronate Sodium | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 14 |
| Temazepam | Temazepam | 49 | suppressed |
| Fluconazole | Fluconazole | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 12 |
| Divalproex Sodium | Divalproex Sodium | 46 | 13 |
| Torsemide | Torsemide | 45 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | 16 |
| Azithromycin | Azithromycin | 43 | 34 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | 12 |
| Metformin Hcl Er | Metformin Hcl | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 12 |
| Levetiracetam | Levetiracetam | 36 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | 14 |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | 12 |
| Prednisone | Prednisone | 34 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | 11 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 29 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 11 |
| Novolin R | Insulin Regular, Human | 29 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Lidocaine | Lidocaine | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 16 |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 26 | 11 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 12 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | 13 |
| Glycopyrrolate | Glycopyrrolate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Haloperidol | Haloperidol | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Lactulose | Lactulose | 21 | 12 |
| Mometasone Furoate | Mometasone Furoate | 21 | 15 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Pentoxifylline | Pentoxifylline | 17 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Klor-Con 8 | Potassium Chloride | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.98 · 1 records | AstraZeneca Pharmaceuticals LP | FARXIGA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error